USANA Health Sciences (USNA) reported Q3 EPS of $0.78, $0.14 worse than the analyst estimate of $0.92. Revenue for the quarter came in at $233 million versus the consensus estimate of $245.95 million.
GUIDANCE:
USANA Health Sciences sees FY2022 EPS of $3.15-$3.40, versus the consensus of $3.90. USANA Health Sciences sees FY2022 revenue of $0.955-0.975 billion, versus the consensus of $1.03 billion.